Moderna and Catalent today announced a collaboration for large-scale, commercial fill-finish manufacturing of Moderna’s mRNA-based COVID-19 vaccine candidate at Catalent’s biologics facility in Bloomington, Indiana.
Catalent today announced the completion of a $3.2 million expansion program at its consumer health manufacturing facilities in Strathroy, Canada and Sorocaba, Brazil.
OneBio Suite offers customers an integrated service to accelerate programs from development to manufacturing, including fill/finish and packaging, and support for clinical supply and commercial launch.
Catalent To Discuss Potential Implications of Brexit on Clinical Supply. SOMERSET, N.J. – March 8, 2018 — Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and d…
Catalent Experts to Present at CTS Europe and CTS New England. Catalent Experts to Present at CTS Europe and CTS New England. SOMERSET, N.J. – March 5, 2019 — Catalent Pharma Solutions, a global leade…
